HRP20230745T3 - Spojevi morfina - Google Patents
Spojevi morfinaInfo
- Publication number
- HRP20230745T3 HRP20230745T3 HRP20230745TT HRP20230745T HRP20230745T3 HR P20230745 T3 HRP20230745 T3 HR P20230745T3 HR P20230745T T HRP20230745T T HR P20230745TT HR P20230745 T HRP20230745 T HR P20230745T HR P20230745 T3 HRP20230745 T3 HR P20230745T3
- Authority
- HR
- Croatia
- Prior art keywords
- diseases
- compound
- formula
- disorders
- hbr salt
- Prior art date
Links
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 24
- 208000002193 Pain Diseases 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 230000036407 pain Effects 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical group C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims 8
- 206010054196 Affect lability Diseases 0.000 claims 7
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 6
- 208000006289 Rett Syndrome Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 4
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 4
- 229910052805 deuterium Inorganic materials 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 230000000155 isotopic effect Effects 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 229960001404 quinidine Drugs 0.000 claims 4
- 206010003805 Autism Diseases 0.000 claims 3
- 208000020706 Autistic disease Diseases 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- 206010011224 Cough Diseases 0.000 claims 3
- 206010012335 Dependence Diseases 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 3
- 208000007101 Muscle Cramp Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 206010029350 Neurotoxicity Diseases 0.000 claims 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims 3
- 208000005392 Spasm Diseases 0.000 claims 3
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 3
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- 208000029028 brain injury Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004431 deuterium atom Chemical group 0.000 claims 3
- 210000005069 ears Anatomy 0.000 claims 3
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims 3
- 210000000867 larynx Anatomy 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 229960000485 methotrexate Drugs 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 231100000228 neurotoxicity Toxicity 0.000 claims 3
- 230000007135 neurotoxicity Effects 0.000 claims 3
- 230000003085 retinopathic effect Effects 0.000 claims 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims 3
- 208000011293 voice disease Diseases 0.000 claims 3
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 claims 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 2
- 229960002870 gabapentin Drugs 0.000 claims 2
- 229960002085 oxycodone Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229960004482 quinidine sulfate Drugs 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/493—Physical analysis of biological material of liquid biological material urine
Claims (15)
1. Sol HBr spoja formule (I):
[image]
pri čemu je faktor izotopskog obogaćivanja za svaki naznačeni atom deuterija najmanje 6000.
2. Sol HBr spoja formule (I) prema zahtjevu 1, naznačena time što je izotopski faktor obogaćivanja za svaki naznačeni atom deuterija najmanje 6333.3.
3. Sol HBr spoja formule (I) prema zahtjevu 1, naznačena time što je izotopski faktor obogaćivanja za svaki naznačeni atom deuterija najmanje 6466.7.
4. Sol HBr spoja formule (I) prema bilo kojem od zahtjeva 1-3, naznačena time što je bilo koji atom koji nije označen kao deuterij prisutan u svojoj prirodnoj izotopskoj zastupljenosti.
5. Farmaceutski pripravak koji sadrži sol HBr spoja formule (I) prema bilo kojem od zahtjeva 1-4 i farmaceutski prihvatljiv nosač.
6. Sol HBr spoja formule (I) prema bilo kojem od zahtjeva 1-4, ili farmaceutski pripravak prema zahtjevu 5, za uporabu u liječenju bolesti ili stanja odabranog između emocionalne labilnosti; pseudobulbarnog afekta; autizama; neurološkog poremećaja; neurodegenerativne bolesti; ozljede mozga; tegoba ili poremećaja svijesti; kardiovaskularne bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatske bolesti; bolesti ili poremećaja uzrokovanih apoptozom induciranom homocisteinom; bolesti ili poremećaja uzrokovanih povišenim razinama homocisteina; kronične boli; neizlječive boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napadaja; zujanja u ušima; seksualne disfunkcije; nepopustljivog kašlja; dermatitisa; poremećaja ovisnosti; Rettovog sindroma (RTT); poremećaja glasa zbog nekontroliranih grčeva mišića grkljana; neurotoksičnosti metotreksata; i umora uzrokovanog rakom.
7. Sol HBr spoja formule (I) prema bilo kojem od zahtjeva 1-4, ili farmaceutski pripravak prema zahtjevu 5, za uporabu u liječenju neuropatske boli.
8. Sol HBr spoja formule (I) prema bilo kojem od zahtjeva 1-4, ili farmaceutski pripravak prema zahtjevu 5, za uporabu u liječenju pseudobulbarnog afekta.
9. Farmaceutski pripravak prema zahtjevu 5, nadalje sadrži drugo terapeutsko sredstvo korisno u liječenju ili prevenciji bolesti ili stanja odabranog između emocionalne labilnosti; pseudobulbarnog afekta; autizama; neurološkog poremećaja; neurodegenerativne bolesti; ozljede mozga; tegoba ili poremećaja svijesti; kardiovaskularne bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatske bolesti; bolesti ili poremećaja uzrokovanih apoptozom induciranom homocisteinom; bolesti ili poremećaja uzrokovanih povišenim razinama homocisteina; kronične boli; neizlječive boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napadaja; zujanja u ušima; seksualne disfunkcije; nepopustljivog kašlja; dermatitisa; poremećaja ovisnosti; Rettovog sindroma (RTT); poremećaja glasa zbog nekontroliranih grčeva mišića grkljana; neurotoksičnosti metotreksata; i umora uzrokovanog rakom.
10. Farmaceutski pripravak prema zahtjevu 9, naznačen time što je drugo terapeutsko sredstvo odabrano između kinidina, kinidin sulfata, oksikodona, i gabapentina.
11. Farmaceutski pripravak prema zahtjevu 10, koji sadrži 10-60 mg soli HBr spoja formule (I) prema bilo kojem od zahtjeva 1-4, i 2.5-30 mg kinidina.
12. Odvojeni oblici doziranja:
(i) sol HBr spoja formule (I) prema bilo kojem od zahtjeva 1-4, ili farmaceutski pripravak prema zahtjevu 5; i
(ii) drugo terapeutsko sredstvo korisno u liječenju ili prevenciji bolesti ili stanja odabranog između emocionalne labilnosti; pseudobulbarnog afekta; autizama; neurološkog poremećaja; neurodegenerativne bolesti; ozljede mozga; tegoba ili poremećaja svijesti; kardiovaskularne bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatske bolesti; bolesti ili poremećaja uzrokovanih apoptozom induciranom homocisteinom; bolesti ili poremećaja uzrokovanih povišenim razinama homocisteina; kronične boli; neizlječive boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napadaja; zujanja u ušima; seksualne disfunkcije; nepopustljivog kašlja; dermatitisa; poremećaja ovisnosti; Rettovog sindroma (RTT); poremećaja glasa zbog nekontroliranih grčeva mišića grkljana; neurotoksičnosti metotreksata; i umora uzrokovanog rakom,
pri čemu su navedena sol HBr spoja formule (I), ili navedeni farmaceutski pripravak, i navedeno drugo terapeutsko sredstvo međusobno povezani.
13. Odvojeni oblici doziranja prema zahtjevu 12, naznačeni time što je navedeno drugo terapeutsko sredstvo odabrano između kinidina, kinidin sulfata, oksikodona, i gabapentina.
14. Odvojeni oblici doziranja prema zahtjevu 12, koji sadrže 10-60 mg soli HBr spoja formule (I) i 2.5-30 mg kinidina.
15. Paket koji sadrži odvojene oblike doziranja prema bilo kojem od zahtjeva 12-14.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91513007P | 2007-05-01 | 2007-05-01 | |
| US91666207P | 2007-05-08 | 2007-05-08 | |
| US97604407P | 2007-09-28 | 2007-09-28 | |
| EP20200633.4A EP3825306B8 (en) | 2007-05-01 | 2008-04-30 | Morphinan compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230745T3 true HRP20230745T3 (hr) | 2023-10-27 |
Family
ID=51894365
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230745TT HRP20230745T3 (hr) | 2007-05-01 | 2008-04-30 | Spojevi morfina |
| HRP20140903AT HRP20140903T1 (hr) | 2007-05-01 | 2014-09-22 | Morfinski spojevi |
| HRP20150809TT HRP20150809T1 (hr) | 2007-05-01 | 2015-07-24 | Spojevi morfinana |
| HRP20150848TT HRP20150848T1 (hr) | 2007-05-01 | 2015-08-10 | Morfinski spojevi |
| HRP20160521TT HRP20160521T8 (hr) | 2007-05-01 | 2016-05-16 | Morfinski spojevi |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140903AT HRP20140903T1 (hr) | 2007-05-01 | 2014-09-22 | Morfinski spojevi |
| HRP20150809TT HRP20150809T1 (hr) | 2007-05-01 | 2015-07-24 | Spojevi morfinana |
| HRP20150848TT HRP20150848T1 (hr) | 2007-05-01 | 2015-08-10 | Morfinski spojevi |
| HRP20160521TT HRP20160521T8 (hr) | 2007-05-01 | 2016-05-16 | Morfinski spojevi |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9314440B2 (hr) |
| EP (5) | EP3093290B1 (hr) |
| BR (1) | BRPI0811478B8 (hr) |
| CA (3) | CA2945581C (hr) |
| CY (1) | CY1117826T1 (hr) |
| DK (4) | DK2522668T3 (hr) |
| ES (5) | ES2577477T3 (hr) |
| FI (1) | FI3825306T3 (hr) |
| HK (5) | HK1178154A1 (hr) |
| HR (5) | HRP20230745T3 (hr) |
| HU (3) | HUE063526T2 (hr) |
| LT (1) | LT3825306T (hr) |
| PL (3) | PL2792662T3 (hr) |
| PT (5) | PT2792662T (hr) |
| SI (2) | SI3825306T1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE063526T2 (hu) | 2007-05-01 | 2024-01-28 | Concert Pharmaceuticals Ind Inc | Morfinvegyületek |
| MX341177B (es) * | 2007-05-01 | 2016-08-10 | Concert Pharmaceuticals Inc | Compuestos de morfina. |
| WO2017020002A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| CA2994153A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| WO2017064876A1 (ja) | 2015-10-14 | 2017-04-20 | 学校法人 久留米大学 | グレリンを有効成分として含有するレット症候群（ｒｔｔ）の予防・治療剤 |
| EP3570842A1 (en) | 2017-01-19 | 2019-11-27 | Donald Danforth Plant Science Center | Morphinan n-demethylase isolated from themethylobacterium |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US38115A (en) | 1863-04-07 | Improvement in turning edges of plates or metal sheets | ||
| GB713146A (en) | 1951-10-18 | 1954-08-04 | Roche Products Ltd | Anti-cough agents comprising (ú½)-3-hydroxy-n-methyl-morphinane ethers and process for the manufacture thereof |
| US4316888A (en) | 1980-04-15 | 1982-02-23 | Nelson Research & Development Co. | Method and composition of reducing pain |
| US4446140A (en) | 1981-12-10 | 1984-05-01 | Nelson Research & Development Company | Method and composition for treating mouth pain |
| JPS6089474A (ja) | 1983-10-20 | 1985-05-20 | Toyo Pharma- Kk | モルフイナン誘導体，その製造方法，及び該化合物を含有する抗腫瘍剤 |
| US4694010A (en) | 1985-08-16 | 1987-09-15 | New York University | Anticonvulsant compositions and method |
| US4898860A (en) | 1985-08-16 | 1990-02-06 | New York University | Anticonvulsant composition and method |
| US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5366980A (en) | 1991-06-17 | 1994-11-22 | Smith Richard A | Use of dextromethorphan and an oxidase inhibitor to treat dermatitis |
| US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
| US5350756A (en) | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| US5336980A (en) | 1992-12-10 | 1994-08-09 | Leopold Kostal Gmbh & Co. | Apparatus and method for controlling a windshield wiping system |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| KR20040068613A (ko) | 1994-03-25 | 2004-07-31 | 이소테크니카 인코포레이티드 | 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물 |
| USRE38115E1 (en) | 1994-09-22 | 2003-05-06 | Center For Neurologic Study | Dextromethorphan and an oxidase inhibitor for treating intractable conditions |
| US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6197830B1 (en) | 1995-09-22 | 2001-03-06 | Bruce M. Frome | Method for achieving relief from sympathetically mediated pain |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| CH690817A5 (de) | 1996-09-03 | 2001-01-31 | Flachsmann Ag Emil | Verfahren zur Herstellung eines stabilen, homogenen, von Folgeprodukten freien oder nahezu freien Extraktes. |
| US6187782B1 (en) | 1997-03-27 | 2001-02-13 | Toray Industries, Inc. | Morphinane derivatives and medicinal use thereof |
| US6884429B2 (en) | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
| EP1051163A2 (en) | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion |
| US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| DE60001623T2 (de) | 1999-12-03 | 2003-12-18 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| US6362226B2 (en) | 1999-12-08 | 2002-03-26 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
| US20050129783A1 (en) | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
| US6780871B2 (en) | 2001-01-29 | 2004-08-24 | Albany Medical College | Methods and compositions for treating addiction disorders |
| US20040087479A1 (en) | 2001-04-30 | 2004-05-06 | Sosnowski Robert E. | Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases |
| US6583152B2 (en) | 2001-04-30 | 2003-06-24 | Dexgen Pharmaceuticals, Inc. | Composition for reducing the risk or progression of cardiovascular diseases |
| JP4101661B2 (ja) | 2001-05-03 | 2008-06-18 | エフ．ホフマン−ラ ロシュ アーゲー | 非晶質メシル酸ネルフィナビルの製薬剤形 |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| UA77234C2 (en) | 2001-12-05 | 2006-11-15 | Wyeth Corp | Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants) |
| MXPA04011327A (es) | 2002-05-17 | 2005-08-15 | Jenken Biosciences Inc | Opioides y compuestos similares a opioides y usos de los mismos. |
| TWI326214B (en) | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| DE102004009445A1 (de) | 2004-02-27 | 2005-09-29 | Chemetall Gmbh | Verfahren zur Herstellung von Alkyllithiumverbindungen und Aryllithiumverbindungen durch Reaktionsverfolgung mittels IR-Spektroskopie |
| CA2576232C (en) | 2004-05-14 | 2009-10-27 | Green Cross Corp. | Neuroprotective properties of dextrorotatory morphinans |
| JP2008514706A (ja) | 2004-09-29 | 2008-05-08 | コーディス・コーポレイション | 安定非晶質ラパマイシン様化合物の薬学的投与形態 |
| US20070191411A1 (en) | 2004-10-07 | 2007-08-16 | Smith Richard A | Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor |
| US7114547B2 (en) | 2005-01-11 | 2006-10-03 | Sullivan Michael R | Casting ring |
| AU2006274037B2 (en) | 2005-07-26 | 2012-04-26 | Takeda Gmbh | Isotopically substituted pantoprazole |
| JP5301991B2 (ja) | 2005-07-29 | 2013-09-25 | コンサート ファーマシューティカルズ インコーポレイテッド | 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体 |
| CN101309917B (zh) | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| AU2007285845A1 (en) | 2006-08-16 | 2008-02-21 | Auspex Pharmaceuticals, Inc. | Preparation and utility of opioid analgesics |
| WO2008030382A1 (en) | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| WO2008097924A2 (en) | 2007-02-05 | 2008-08-14 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders |
| HUE063526T2 (hu) | 2007-05-01 | 2024-01-28 | Concert Pharmaceuticals Ind Inc | Morfinvegyületek |
| CN102964302B (zh) | 2007-05-01 | 2015-10-21 | 康塞特医药品公司 | 吗啡烷化合物 |
| PL3248978T3 (pl) | 2008-09-19 | 2019-12-31 | Concert Pharmaceuticals Inc. | Zdeuterowane związki morfinanu |
| US20120083487A1 (en) | 2008-10-30 | 2012-04-05 | Amanda Thomas | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury |
| JP6525419B2 (ja) | 2015-01-15 | 2019-06-05 | 株式会社半導体エネルギー研究所 | 二次電池 |
-
2008
- 2008-04-30 HU HUE20200633A patent/HUE063526T2/hu unknown
- 2008-04-30 PL PL14173190.1T patent/PL2792662T3/pl unknown
- 2008-04-30 SI SI200832212T patent/SI3825306T1/sl unknown
- 2008-04-30 CA CA2945581A patent/CA2945581C/en active Active
- 2008-04-30 ES ES14173190.1T patent/ES2577477T3/es active Active
- 2008-04-30 HU HUE11000764A patent/HUE025569T2/en unknown
- 2008-04-30 SI SI200831620A patent/SI2792662T1/sl unknown
- 2008-04-30 ES ES12176544.0T patent/ES2536984T3/es active Active
- 2008-04-30 BR BRPI0811478A patent/BRPI0811478B8/pt active IP Right Grant
- 2008-04-30 EP EP16163718.6A patent/EP3093290B1/en active Active
- 2008-04-30 FI FIEP20200633.4T patent/FI3825306T3/fi active
- 2008-04-30 PT PT141731901T patent/PT2792662T/pt unknown
- 2008-04-30 EP EP14173190.1A patent/EP2792662B1/en active Active
- 2008-04-30 HU HUE14173190A patent/HUE029782T2/en unknown
- 2008-04-30 CA CA3208128A patent/CA3208128A1/en active Pending
- 2008-04-30 DK DK12176544.0T patent/DK2522668T3/en active
- 2008-04-30 CA CA3056205A patent/CA3056205C/en active Active
- 2008-04-30 DK DK20200633.4T patent/DK3825306T3/da active
- 2008-04-30 ES ES12176476.5T patent/ES2523286T3/es active Active
- 2008-04-30 PT PT121765440T patent/PT2522668E/pt unknown
- 2008-04-30 PT PT121764765T patent/PT2522667E/pt unknown
- 2008-04-30 EP EP20200633.4A patent/EP3825306B8/en active Active
- 2008-04-30 HR HRP20230745TT patent/HRP20230745T3/hr unknown
- 2008-04-30 PT PT110007648T patent/PT2357183E/pt unknown
- 2008-04-30 PT PT202006334T patent/PT3825306T/pt unknown
- 2008-04-30 PL PL20200633.4T patent/PL3825306T3/pl unknown
- 2008-04-30 DK DK11000764.8T patent/DK2357183T3/en active
- 2008-04-30 LT LTEP20200633.4T patent/LT3825306T/lt unknown
- 2008-04-30 EP EP17206213.5A patent/EP3357923B1/en active Active
- 2008-04-30 EP EP11000764.8A patent/EP2357183B1/en active Active
- 2008-04-30 ES ES11000764.8T patent/ES2545617T3/es active Active
- 2008-04-30 DK DK14173190.1T patent/DK2792662T3/da active
- 2008-04-30 ES ES20200633T patent/ES2951028T3/es active Active
- 2008-04-30 PL PL11000764T patent/PL2357183T3/pl unknown
-
2010
- 2010-07-22 HK HK13105154.6A patent/HK1178154A1/xx unknown
- 2010-07-22 HK HK11109620.6A patent/HK1155442A1/xx unknown
- 2010-07-22 HK HK13105601.5A patent/HK1178889A1/xx unknown
- 2010-07-22 HK HK15101294.4A patent/HK1201058A1/zh unknown
-
2014
- 2014-07-17 US US14/334,227 patent/US9314440B2/en active Active
- 2014-09-22 HR HRP20140903AT patent/HRP20140903T1/hr unknown
-
2015
- 2015-07-24 HR HRP20150809TT patent/HRP20150809T1/hr unknown
- 2015-08-10 HR HRP20150848TT patent/HRP20150848T1/hr unknown
-
2016
- 2016-03-11 US US15/068,404 patent/US9868976B2/en active Active
- 2016-05-16 HR HRP20160521TT patent/HRP20160521T8/hr unknown
- 2016-07-05 CY CY20161100624T patent/CY1117826T1/el unknown
-
2017
- 2017-05-02 HK HK19101064.8A patent/HK1259133A1/zh unknown
- 2017-12-12 US US15/839,387 patent/US20180327809A1/en not_active Abandoned
-
2020
- 2020-12-14 US US17/120,880 patent/US11473123B2/en active Active
-
2022
- 2022-09-12 US US17/942,555 patent/US20240093265A1/en active Pending
-
2023
- 2023-04-25 US US18/306,710 patent/US20240117407A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120317T1 (hr) | Spojevi morfinana | |
| HRP20150809T1 (hr) | Spojevi morfinana | |
| JP2021105032A5 (hr) | ||
| HRP20171587T1 (hr) | Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola | |
| JP2013526544A5 (hr) | ||
| JP2012505238A5 (hr) | ||
| US20050245460A1 (en) | Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders | |
| CA2719749A1 (en) | Methods for treating disorders using nmda nr2b-subtype selective antagonist | |
| MXPA02001820A (es) | Composicion que comprende un material de tramadol y un farmaco anticonvulsivo. | |
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| MX2010013766A (es) | Rasagilina para modificacion de enfermedad de parkinson. | |
| JP2010535801A5 (hr) | ||
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| JP2008515801A5 (hr) | ||
| MX2012009079A (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| EA201170976A1 (ru) | Получение и виды терапевтического применения (2s,3r)-n-2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)-3,5-дифторбензамида | |
| SI2501234T1 (en) | METHODS AND INGREDIENTS FOR TREATMENT OF SYMPTOMS RELATED TO POST-TRAUMATIC STRESS EMISSIONS WITH THE USE OF CYCLOBENZAPRINE | |
| JP2016509030A5 (hr) | ||
| WO2008030830A3 (en) | Sustained-release composition and method of use thereof | |
| BR112014029478A2 (pt) | profármaco de aminoácido contendo flúor | |
| US20150111916A9 (en) | Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof | |
| JP2014513130A5 (hr) | ||
| WO2008000743A3 (en) | Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists | |
| US20140296275A1 (en) | Combinations of an Opioid/TLR4 Antagonist and an Alpha-2-Delta Ligand for Use in the Treatment of Pain | |
| MX2012006955A (es) | Compuestos para el tratamiento de trastornos neurologicos. |